Browsing: Novo

Wilson, P. C. & Andrews, S. F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. 12, 709–719…

Intent on growing its leading position in obesity and weight management drugs, Novo Nordisk has made an unsolicited, approximately up-to-$9…

If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B)…

Danish biosolutions company Novonesis and healthcare company Novo Nordisk have entered a research partnership to explore the role of the…

Novo Nordisk (NASDAQ Copenhagen: NOVO-B) inflicted much pain—and much-needed pain—on the company when president and CEO Maziar (Mike) Doustdar announced…

The Danish firms plan to develop and test synbiotic dietary supplements – combining probiotics and prebiotics – that can have…